Intraperitoneal chemotherapy is a treatment for cancers in the abdomen or belly area. This treatment delivers anti-cancer drugs directly into the peritoneal cavity, the area in the belly that contains ...

Standard chemotherapy for newly diagnosed ovarian cancer is a platinum–taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel ...

In patients with tumors confined to the peritoneal cavity, there is established pharmacokinetic and tumor biology-related evidence that intraperitoneal drug administration is advantageous. Three large ...

Adding intraperitoneal paclitaxel to intravenous paclitaxel plus oral S-1 improved overall survival in patients with gastric cancer and peritoneal metastasis, extending median survival to 19.4 months ...

In clinical practice, only a few risk factors remain that can be modified based on the decisions of patients and their physicians. The surgical decision making and chemotherapy administration choices, ...

Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation ...

HIPEC is a type of treatment for cancers that have spread within your abdomen. Doctors surgically remove the tumor and then pump heated chemotherapy drugs into your abdominal cavity. Hyperthermic ...

Intraperitoneal (IP) chemotherapy is a type of ovarian cancer treatment in which chemo drugs are directly pumped into your belly cavity (also called peritoneal cavity). When you get chemo this way, it ...

A second-generation intraperitoneal insulin pump — the next-generation MiniMed Implantable Insulin Pump System (MIIPS 2020), which is not yet commercially licensed but can be obtained in some cases on ...

What is intraperitoneal chemotherapy? Your peritoneal (payr-ih-toh-NEE-ul) space is the area between the muscles and organs in your abdomen (belly) (see Figure 1). There is a little fluid between the ...

We undertook an exploratory cross-trial analysis (Figure 1) comparing intraperitoneal cisplatin plus paclitaxel in the patients in the study by Armstrong et al. with intravenous carboplatin plus ...